Alnylam Pharmaceuticals Statistics
Share Statistics
Alnylam Pharmaceuticals has 133.66M shares outstanding. The number of shares has increased by 2.7% in one year.
| Shares Outstanding | 133.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.49% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 127.94M |
| Failed to Deliver (FTD) Shares | 74 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.70M, so 2.87% of the outstanding shares have been sold short.
| Short Interest | 3.70M |
| Short % of Shares Out | 2.87% |
| Short % of Float | 2.89% |
| Short Ratio (days to cover) | 4.6 |
Valuation Ratios
The PE ratio is -54.31 and the forward PE ratio is -220.45.
| PE Ratio | -54.31 |
| Forward PE | -220.45 |
| PS Ratio | 13.08 |
| Forward PS | 12.9 |
| PB Ratio | -108.36 |
| P/FCF Ratio | 569.99 |
| PEG Ratio | n/a |
Enterprise Valuation
Alnylam Pharmaceuticals Inc. has an Enterprise Value (EV) of 25.78B.
| EV / Earnings | -58.55 |
| EV / Sales | 14.1 |
| EV / EBITDA | -99.82 |
| EV / EBIT | -91.36 |
| EV / FCF | 614.57 |
Financial Position
The company has a current ratio of 3.08, with a Debt / Equity ratio of -10.87.
| Current Ratio | 3.08 |
| Quick Ratio | 2.99 |
| Debt / Equity | -10.87 |
| Total Debt / Capitalization | 110.13 |
| Cash Flow / Debt | 0.04 |
| Interest Coverage | -2.33 |
Financial Efficiency
Return on equity (ROE) is 2% and return on capital (ROIC) is -11.64%.
| Return on Equity (ROE) | 2% |
| Return on Assets (ROA) | -0.11% |
| Return on Capital (ROIC) | -11.64% |
| Revenue Per Employee | 870.62K |
| Profits Per Employee | -209.64K |
| Employee Count | 2.10K |
| Asset Turnover | 0.48 |
| Inventory Turnover | 3.48 |
Taxes
| Income Tax | 6.72M |
| Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by 32.4% in the last 52 weeks. The beta is 0.39, so Alnylam Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | 32.4% |
| 50-Day Moving Average | 267.77 |
| 200-Day Moving Average | 218.42 |
| Relative Strength Index (RSI) | 38.53 |
| Average Volume (20 Days) | 769.80K |
Income Statement
In the last 12 months, Alnylam Pharmaceuticals had revenue of $1.83B and earned -$440.24M in profits. Earnings per share was $-3.52.
| Revenue | 1.83B |
| Gross Profit | 1.52B |
| Operating Income | -282.18M |
| Net Income | -440.24M |
| EBITDA | -258.24M |
| EBIT | -282.18M |
| Earnings Per Share (EPS) | -3.52 |
Balance Sheet
The company has $812.69M in cash and $2.68B in debt, giving a net cash position of -$1.87B.
| Cash & Cash Equivalents | 812.69M |
| Total Debt | 2.68B |
| Net Cash | -1.87B |
| Retained Earnings | -7.01B |
| Total Assets | 4.21B |
| Working Capital | 2.13B |
Cash Flow
In the last 12 months, operating cash flow was $104.16M and capital expenditures -$62.21M, giving a free cash flow of $41.95M.
| Operating Cash Flow | 104.16M |
| Capital Expenditures | -62.21M |
| Free Cash Flow | 41.95M |
| FCF Per Share | 0.34 |
Margins
Gross margin is 83.02%, with operating and profit margins of -15.43% and -24.08%.
| Gross Margin | 83.02% |
| Operating Margin | -15.43% |
| Pretax Margin | -23.71% |
| Profit Margin | -24.08% |
| EBITDA Margin | -14.12% |
| EBIT Margin | -15.43% |
| FCF Margin | 2.29% |
Dividends & Yields
ALNY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.44% |
| FCF Yield | 0.13% |
Analyst Forecast
The average price target for ALNY is $300, which is 22.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $300 |
| Price Target Difference | 22.3% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
Scores
| Altman Z-Score | 3.28 |
| Piotroski F-Score | 3 |